Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00129844 · ClinicalTrials.gov registry record · Phase 2
Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer
A Phase 2 study, sponsored by Pharmacyclics.
- Completed
- Registry status
- Phase 2
- Development phase
- 108
- Enrollment target
NCT00129844 is a Phase 2 study that has completed, run by Pharmacyclics. The registered enrollment target is 108 participants.
The verdict
NCT00129844, a Phase 2 study, has completed, sponsored by Pharmacyclics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 108 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effect of MGd in non-small-cell lung cancer (NSCLC) when given alone, and to evaluate the difference between two dosing regimens.
Interventions
- DRUG Motexafin Gadolinium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2005-09 |
| Est. Completion | 2007-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00129844
The ClinicalTrials.gov registry entry for NCT00129844 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pharmacyclics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Motexafin Gadolinium is the first listed.
NCT00129844 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00129844 about?
NCT00129844 is a clinical study titled "Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer". The purpose of this study is to determine the effect of MGd in non-small-cell lung cancer (NSCLC) when given alone, and to evaluate the difference between two dosing regimens.
What is the current status of trial NCT00129844?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 108 participants. The study started on 2005-09. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00129844?
The interventions under investigation include: Motexafin Gadolinium (DRUG).
Who is sponsoring clinical trial NCT00129844?
This trial is sponsored by Pharmacyclics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.